Monday, July 21, 2014

Systemic Treatment of Renal Cell Carcinoma: Programmed Death Ligand 1 Inhibitors

Greater than 80% of renal tumors are renal cell carcinoma (RCC), of which about 70% is of clear-cell pathology.[1]   There are about 64,000 new RCC cases and 14,000 deaths from RCC each year, but due to increased imaging it is thought that we are catching these cancers at an earlier stage, when they are still resectable.  Unfortunately, mortality rates have not decreased and the burden of metastatic disease persists.[2]  Twenty to thirty percent of patients present with metastatic cancer and 20-30% of patients who have resectable disease later return with systemic disease following surgical management, whether it be partial or radical nephrectomy.[3,4] This underscores the necessity of management options outside of surgery.

RCC has largely been termed “chemoresistant,” meaning response to existing cytotoxic chemotherapeutic agents has been limited.  Therefore, cancer doctors and researchers continue to search for different forms of systemic treatments.[5]  In the early 1990s, immunotherapy was successfully used as systemic treatment for RCC.  The idea for this treatment came from the wide range in prognoses among patients with seemingly similar disease burden -- for example, among patients with similarly sized tumors (whether small or large), some were cured with surgery alone while patients with very similar tumors developed metastatic cancer and died.  In addition, a significant proportion of patients would have spontaneous regression of metastatic disease once the primary tumor was surgically removed.  Both of these observations suggest an interaction between the immune system and disease.[6,7] Ultimately, immunotherapies (like IFN-alpha and IL-2) were found to be more effective than previously attempted chemotherapies.  More recently, targeted therapies were developed to interrupt specific portions of the cell-cycle and endothelial attachment processes in clear-cell RCC.[8]

The idea of targeted therapy and theories of the immunoresponsive nature of clear cell RCC were combined to focus on specific parts of the immune interaction.   Among others, one important interaction is the Programmed Death Ligand 1 (PD-L1) interaction between the tumor cells and the immune cells.  T-cells are immune cells that target “foreign” cells in the body and trigger an immune response to kill those cells.  T-cells have receptors that have evolved (through genetic mutations and recombinations) to be specific for different surface proteins that may found in the cells of the body.  In a normal, healthy person, T-cells will even recognize normal, healthy cells.  However there are mechanisms to prevent the T-cell from killing good cells – a process called “anergy” which leads to T-cell death (or apoptosis).  One such signaling pathway is the PD-L1 on the healthy cell interacts with the receptor on the healthy cell (Figure 1).
Figure 1. T-Cell Recognizing Healthy Cell via PD-1-PD-L1 Interaction and Inducing Cell Death (Apoptosis).
If the T-cell identifies a tumor cell, it will not get the normal signal that it is a healthy cell, the T-cell can initiate processes to kill the tumor cell (Figure 2).
Figure 2. T-Cell Recognizing Tumor Cell without PD-1-PD-L1 Interaction.

However, some cancers like kidney cancer, can “trick” the T-cell into thinking the tumor cell is a normal, healthy cell.  One mechanism these cancers use is to express PD-L1, allowing tumor cell to escape the immune system and proliferate (Figure 3).[9]
Figure 3. Tumor Cell Expressing PD-L1 and Avoiding Detection by Immune System.



It has been noted that patients with tumors that have high expression of PD-L1 have a worse prognosis, which further suggests its involvement in the lifecycle of the disease -- although there is significant heterogeneity in expression of PD-L1 within individuals.[10]    Drugs have been developed that target both the PD-L1 on the tumor cells and the PD-1 receptor on the T-cells.  Nivolumab is the drug furthest along in the drug approval process that targets PD-1 on the T-cell.  There have been significant responses to this agent among about 30% patients who had failed treatment with the targeted therapies and enrolled in the trials. Interestingly, responses were only seen in patients who had clear-cell RCC that expressed PD-L1.[11] This response in patients who had failed the first-line targeted therapy shows promise for these novel agents. The heterogeneity of expression suggests it could play a future role in multimodal therapy.


This blog was written by Jason Cohen, Medical Student at Johns Hopkins Medical School.  Jason recently finished a four-week sub-internship at the Brady Urological Institute and gave a presentation to the department on "Programmed Death Ligand 1 Inhibitors: Systemic Treatment of Renal Cell Carcinoma" from which this blog is inspired. Jason is looking forward to a career in urology.






[1]  Siegel R et al. CA Cancer J Clin 2014; 64:9.
[2]  Hollingsworth et al. J Natl Cancer Inst. 2006; 98:1331
[3]  Curti B et al. J Am Med Assoc 2004; 292: 97
[4]  Levi D et al. J Urol 1998; 159: 1163
[5]  Chung EK et al. Am J Clin Oncol 2011; 34: 150
[6]  Oliver RT et al. Br J Urol 1989; 63: 128
[7]  Vogelzang NJ et al. J Urol 1992; 148: 1247
[8]  Rini BI et al. Lancet 2009; 373: 1119
[9]  Dong H et al. Nat Med 2002; 8: 793
[10]  Thompson RH et al. PNAS 2004; 101: 17174
[11]  Topalian SL et al. N Engl J Med 2012; 366: 2443


6 comments:

  1. I would be very thankful if you continue with quality what you are serving right now with your blog. I really enjoyed it. and i really appreciate to you for this. Multi Speciality in Dombivali || Physician and Neurosurgeon in Dombivali || Multispeciality Hospitals in Dombivli

    ReplyDelete
  2. I like the valuable information you provide in your blog. I will bookmark your blog and check again here frequently. I'm quite certain I will learn many new stuff right here! Best of luck for the next! Cancer Surgeon in Dombivli || Urology Center in dombivli || Orthopedic Surgeon in Dombivli

    ReplyDelete
  3. i was just read your blog that was really superb got much pleasure to read that post. please keep sharing post like that.thanks for share with us for this post. Critical Care in Dombivali || Plastic Surgeon in dombivli || Orthopedic Hospital in Dombivli

    ReplyDelete
  4. Very informative and impressive post you have written, this is quite interesting and i have went through it completely, an upgraded information is shared, keep sharing such valuable information. Hospitals in Dombivli || Physiotherapy in Dombivli || Hospital in Dombivli

    ReplyDelete
  5. I have promised myself that I'm going to work hard to raise awareness in young men and women about herbal cure to Renal Cell Carcinoma. I have had Renal Cell Carcinoma for good 10 years, with 3 active episodes. Firstly, I had surgery to remove left kidney, with no further follow up action. Secondly, I had another surgery to remove a mass where the kidney had previously been, followed by radiation therapy but none seem to worked. The tumors began to spread to my lungs. Even tried traditional chemo treatment,and used new oral chemo drugs, holistic healing, Other prescription medication but all failed. There are other trials which were in early stages of development but with no proven track record. It is very hard for anyone to truly know what it is like to have cancer, unless you've been there yourself. I once had a person tell me that they thought they were completely empathetic and thought they could imagine how hard it must be for a cancer victim. After so many trials with little or no improvement, herbal treatment worked the wonders though staying active with work and family contributed to my survival. Don't take NO for an answer when it relates to treatment. Just be positive, be proactive, Get a second opinion. Get a third opinion or as many as it takes. For more information, contact Dr. Allen (drallenchase@gmail.com) for advice and possible solution. Life is to be savored, no matter how long or short it is. Take advantage of all the joyous things in life and know that the harsh things will pass. I feel great

    ReplyDelete
  6. ALL THANKS TO DR WILLIAMS FOR THE GREAT DEED HE HAVE DON FOR MY FAMILY.This information will be useful for Epilepsy patients who is willing to use herbal medicine. My daughter had temporal lobe epilepsy, She had seizure and had a grand mal with rage episode. Our daughter's seizure is constant throughout the day. We had used several medicine which include: Epilim and Keppra, experience seizure control at the cost of serious debilitating side effects. It was during a casual conversation with a friend that I learned about herbal Dr. William, it does not have any side effect. I am glad to say that he has been seizure-free since July 2015 after taking William medicine. this a miracle cure?contact him for more detail (drwilliams098765@gmail.com)

    ReplyDelete